Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients

Immunohistochemical Study of Mitosis-regulatory Proteins in Gastroenteropancreatic Neuroendocrine Neoplasms

(2018) FRANZISKA BRIEST et al.   ANTICANCER RESEARCH

The Immune Landscape of Cancer

(2018) Vésteinn Thorsson et al.   IMMUNITY

Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors

(2018) Jeffrey M. Conroy et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

(2018) Carl Morrison et al.   Journal for ImmunoTherapy of Cancer

The hallmarks of successful anticancer immunotherapy

(2018) Lorenzo Galluzzi et al.   Science Translational Medicine

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

(2018) S. N. Gettinger et al.   Nature Communications

Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer

(2017) Reinhard Büttner et al.   JOURNAL OF CLINICAL ONCOLOGY

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

(2017) Mizuki Nishino et al.   Nature Reviews Clinical Oncology

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

(2017) Hongchao Pan et al.   NEW ENGLAND JOURNAL OF MEDICINE

RNA sequencing-based cell proliferation analysis across 19 cancers identifies a subset of proliferation-informative cancers with a common survival signature

(2017) Ryne C. Ramaker et al.   Oncotarget

Trial watch: Immune checkpoint blockers for cancer therapy

(2017) Claire Vanpouille-Box et al.   OncoImmunology

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1

(2016) Joohee Sul et al.   ONCOLOGIST

Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing

(2016) Benjamin E. Paluch et al.   Oncotarget

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE